The human genetic and immunological determinants of the clinical manifestations of SARS-CoV-2 infection: Towards personalised medicine

HealthHORIZON-RIAID: 101057100
EC Contribution
โ‚ฌ67,181
Consortium Size
22 orgs
Start Year
2022
โ–ถSummary

The consequences of SARS-CoV-2 exposure range from a lack of infection to lethal COVID-19. This immense inter-individual clinical variability is the key scientific and medical enigma in the field. While age and certain co-morbidities are known to influence disease outcome, these parameters do not explain all variation. In addition, there are other SARS-CoV-2 phenotypes of clinical importance: multisystem inflammatory syndrome in children and adults (MIS-C/A), and longCOVID. An important breakthrough to unravel the pathogenesis of COVID-19 came from our two Science papers that were recognized by Nature among the top 10 discoveries of 2020. We found that about 4% of patients with critical COVID-19 pneumonia had inborn errors of immunity (IEI) that impair TLR3- and IRF7-dependent type I interferon (IFN) immunity and at least 10% of the patients carried pre-existing autoantibodies (auto-Abs) neutralizing type I IFNs. These findings pave the way for further studies of COVID-19 pneumonia and other SARS-CoV-2 infection phenotypes and form the basis of the present research proposal, UNDINE, which follows a ""bed side to bench"" and ""bench to bed side"" approach, with the following objectivies i) to decipher the genetic and immunological basis of the various SARS-CoV-2 disease manifestations, to identify individuals at increased risk of critical COVID-19, post-infectious immunological complications, and vaccine failure iii) to develop ready-to-use diagnostic tests for large-scale detection of auto-Abs to type I IFNs and propose novel preventive and therapeutic approaches, based on the pathogenesis of SARS-CoV-2 infection for translation into personalised medicine. To achieve these goals, our project will coordinate a European multidisciplinary and translational research effort relying on a strong and synergistic combination of assets, including unique cohorts from 11 EU countries and state-of-the art human genetic, immunological and virological expertises and technologies.""

Consortium (22)

AARHUS UNIVERSITET
coordinator
๐Ÿ‡ฉ๐Ÿ‡ฐ AARHUS UNIVERSITETSHOSPITALDK
partner
๐Ÿ‡ซ๐Ÿ‡ท BIOMERIEUX SAFR
partner
๐Ÿ‡จ๐Ÿ‡ญ CENTRE HOSPITALIER UNIVERSITAIRE VAUDOISCH
partner
๐Ÿ‡ฉ๐Ÿ‡ช DEUTSCHES PRIMATENZENTRUM GMBHDE
partner
๐Ÿ‡จ๐Ÿ‡ญ ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNECH
partner
๐Ÿ‡ช๐Ÿ‡ธ FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCAES
partner
๐Ÿ‡ช๐Ÿ‡ธ FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGEES
partner
๐Ÿ‡ฌ๐Ÿ‡ท IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINONGR
partner
๐Ÿ‡ฌ๐Ÿ‡ง IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINEGB
partner
๐Ÿ‡ช๐Ÿ‡ธ INSTITUT CATALA DE LA SALUTES
partner
๐Ÿ‡ช๐Ÿ‡ธ INSTITUT DE INVESTIGACIO EN CIENCIES DE LA SALUT GERMANS TRIAS I PUJOLES
partner
๐Ÿ‡ซ๐Ÿ‡ท INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALEFR
partner
๐Ÿ‡ซ๐Ÿ‡ท INSTITUT PASTEURFR
partner
๐Ÿ‡ธ๐Ÿ‡ช KAROLINSKA INSTITUTETSE
partner
๐Ÿ‡ง๐Ÿ‡ช KATHOLIEKE UNIVERSITEIT LEUVENBE
partner
๐Ÿ‡ฎ๐Ÿ‡น OSPEDALE SAN RAFFAELE SRLIT
partner
๐Ÿ‡ช๐Ÿ‡ธ SERVICIO MADRILENO DE SALUDES
partner
๐Ÿ‡ช๐Ÿ‡ช TARTU ULIKOOLEE
partner
๐Ÿ‡ฎ๐Ÿ‡ช THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLINIE
partner
๐Ÿ‡ฎ๐Ÿ‡น UNIVERSITA DEGLI STUDI DI ROMA TOR VERGATAIT
partner
๐Ÿ‡ณ๐Ÿ‡ฑ UNIVERSITAIR MEDISCH CENTRUM UTRECHTNL
partner